Delivery Order SPE2DB20D9127-SPE2DB25FPQF7
Award Date
4/7/25
Potential Completion Date
4/28/25
Potential Value
$53K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of TYSABRI 300 MG/15 ML VIAL 15ML, a specialized pharmaceutical product, with a ceiling value of $5,262.76 and a period of performance through April 22, 2025. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,547.76 contract is for the delivery of Tysabri 300 mg/15 ml vials. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,316.36 firm fixed-price contract is for the delivery of Tysabri 300 mg/15 ml vials. DMS Pharmaceutical Group holds a larger, single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to issue delivery...
The Defense Logistics Agency (DLA) awarded a $51,581.80 firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of TYSABRI 300 MG/15 ML VIAL 15ML. This delivery order is part of a larger indefinite delivery vehicle (IDV) contract, SPE2DB24FPQG7, valued at up to $4,999,999 through 2025, which enables DLA to issue delivery orders for a broad range of pharmaceutical products to support military medical facilities. DMS Pharmaceutical...
This federal contract award, valued at $15,474.54, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the delivery of Tysabri 300 mg/15 ml vials. The contract is a firm fixed-price delivery order with no set-aside designation. It is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $51,581.80, is for the delivery of the pharmaceutical product Tysabri 300 mg/15 ml vial with a completion date of October 16, 2023. DMS Pharmaceutical Group Inc. holds a large Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was issued by the Defense Logistics Agency (DLA) under the Medical Supply Chain division. The $10,316.36 firm fixed-price delivery order covers the supply of Tysabri 300 mg/15 ml vial, with an ultimate completion date of October 31, 2024. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group to provide a comprehensive...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, by the Defense Logistics Agency (DLA) under the SPE2DB procurement program. The contract is for $10,316.36 and covers the delivery of TYSABRI 300 MG/15 ML VIAL 15ML, with a period of performance through July 2, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $51,581.80 contract is for the delivery of TYSABRI 300 MG/15 ML vials to support the medical supply needs of military healthcare facilities. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which allows...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $21,051.08 and covers the supply of Tysabri, a 300 mg/15 ml vial medication, with a period of performance through January 27, 2025. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at...